SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Zhen-Xin Zhang, Honglei Chen, Sheng-Di Chen, Ming Shao, Sheng-Gang Sun, Qiu-Min Qu, Bao-Rong Zhang, Yi-Ming Liu, Qun Xu, Xia Wan, Ling Li, Hong-Bo Wen, Xia Chen, Hai-Bo Chen, Zhen-Guo Liu, Jian Wang, Gang Wang, Chinese culture permeation in the treatment of Parkinson disease: a cross-sectional study in four regions of China, BMC Research Notes, 2014, 7, 1, 65

    CrossRef

  2. 2
    Raja Mehanna, Suzanne Moore, J. Gabriel Hou, Aliya I. Sarwar, Eugene C. Lai, Comparing clinical features of young onset, middle onset and late onset Parkinson's disease, Parkinsonism & Related Disorders, 2014, 20, 5, 530

    CrossRef

  3. 3
    Nir Giladi, Liesbet Ghys, Erwin Surmann, Babak Boroojerdi, Joseph Jankovic, Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease, Parkinsonism & Related Disorders, 2014, 20, 12, 1345

    CrossRef

  4. 4
    Amaal Al Dakheel, Isabelle Beaulieu-Boire, Susan H Fox, Emerging drugs for levodopa-induced dyskinesia, Expert Opinion on Emerging Drugs, 2014, 19, 3, 415

    CrossRef

  5. 5
    C. Brefel-Courbon, C. Arcari, C. Mohara, J. Dupouy, F. Ory-Magne, La place de l’éducation thérapeutique chez le parkinsonien âgé, Les cahiers de l'année gérontologique, 2014, 6, 4, 169

    CrossRef

  6. 6
    H. Z. Hashim, M. I. Norlinah, W. Y. Nafisah, H. J. Tan, A. A. Raymond, A. M. Tamil, Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease, International Journal of Neuroscience, 2014, 124, 3, 187

    CrossRef

  7. 7
    S. Mazzucchi, D. Frosini, A. Ripoli, V. Nicoletti, G. Linsalata, U. Bonuccelli, R. Ceravolo, Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease, Acta Neurologica Scandinavica, 2014, 130, 6
  8. 8
    Sean Austin O. Lim, Un Jung Kang, Daniel S. McGehee, Striatal cholinergic interneuron regulation and circuit effects, Frontiers in Synaptic Neuroscience, 2014, 6,

    CrossRef

  9. 9
    Antonio Cerasa, Maria Salsone, Maurizio Morelli, Pierfrancesco Pugliese, Gennarina Arabia, Cecilia M. Gioia, Fabiana Novellino, Aldo Quattrone, Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias, Parkinsonism & Related Disorders, 2013, 19, 10, 883

    CrossRef

  10. 10
    Amit Batla, Maria Stamelou, Niccolo Mencacci, Anthony H. Schapira, Kailash P. Bhatia, Ropinirole monotherapy induced severe reversible dyskinesias in Parkinson's disease, Movement Disorders, 2013, 28, 8
  11. 11
    Cara A Pecina, Alberto J Espay, Parkinson’s Disease: Medical and Surgical Treatment, 2013,

    CrossRef

  12. 12
    David Salat, Eduardo Tolosa, Handbook of Parkinson's Disease, Fifth Edition, 2013,

    CrossRef

  13. 13
    David Salat, Eduardo Tolosa, Handbook of Parkinson’s Disease, 2013,

    CrossRef

  14. 14
    Nicola Tambasco, Simone Simoni, Erica Marsili, Elisa Sacchini, Donatella Murasecco, Gabriela Cardaioli, Aroldo Rossi, Paolo Calabresi, Clinical Aspects and Management of Levodopa-Induced Dyskinesia, Parkinson's Disease, 2012, 2012, 1

    CrossRef

  15. 15
    Nico J. Weerkamp, Sytse U. Zuidema, Gerrit Tissingh, Petra J. E. Poels, Marten Munneke, Raymond T. C. M. Koopmans, Bastiaan R. Bloem, Motor Profile and Drug Treatment of Nursing Home Residents with Parkinson's Disease, Journal of the American Geriatrics Society, 2012, 60, 12
  16. 16
    Dong-Churl Suh, Rajesh Pahwa, Usha Mallya, Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia, Journal of the Neurological Sciences, 2012, 319, 1-2, 24

    CrossRef

  17. 17
    Pedro J. García-Ruiz, Javier del Val, Ignacio Mahillo Fernández, Antonio Herranz, What Factors Influence Motor Complications in Parkinson Disease?, Clinical Neuropharmacology, 2012, 35, 1, 1

    CrossRef

  18. 18
    Emma L. Lane, Christian Winkler, Functional Neural Transplantation III - Primary and Stem Cell Therapies for Brain Repair, Part I, 2012,

    CrossRef

  19. 19
    J. Eric Ahlskog, Cheaper, Simpler, and Better: Tips for Treating Seniors With Parkinson Disease, Mayo Clinic Proceedings, 2011, 86, 12, 1211

    CrossRef

  20. 20
    Christopher A. Lieu, Milind Deogaonkar, Roy A.E. Bakay, Thyagarajan Subramanian, Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys, Parkinsonism & Related Disorders, 2011, 17, 1, 34

    CrossRef

  21. 21
    James K. R. Stevenson, Pouria Talebifard, Edna Ty, Meeko M. K. Oishi, Martin J. McKeown, Dyskinetic Parkinson’s disease patients demonstrate motor abnormalities off medication, Experimental Brain Research, 2011, 214, 3, 471

    CrossRef

  22. 22
    Antonio Cerasa, Demetrio Messina, Pierfrancesco Pugliese, Maurizio Morelli, Pierluigi Lanza, Maria Salsone, Fabiana Novellino, Giuseppe Nicoletti, Gennarina Arabia, Aldo Quattrone, Increased prefrontal volume in PD with levodopa-induced dyskinesias: A voxel-based morphometry study, Movement Disorders, 2011, 26, 5
  23. 23
    K. K. Johansen, J. V. Jørgensen, L. R. White, M. J. Farrer, J. O. Aasly, Parkinson-related genetics in patients treated with deep brain stimulation, Acta Neurologica Scandinavica, 2011, 123, 3
  24. 24
    Santiago Perez-Lloret, María Verónica Rey, Luca Ratti, Olivier Rascol, Pramipexole for the treatment of early Parkinson’s disease, Expert Review of Neurotherapeutics, 2011, 11, 7, 925

    CrossRef

  25. 25
    Mirdhu M. Wickremaratchi, M. Duleeka W. Knipe, B.S. Dwarakanath Sastry, Elizabeth Morgan, Anne Jones, Rachel Salmon, Richard Weiser, Maralyn Moran, Debbie Davies, Louise Ebenezer, Sandip Raha, Neil P. Robertson, Christopher C. Butler, Yoav Ben-Shlomo, Huw R. Morris, The motor phenotype of Parkinson's disease in relation to age at onset, Movement Disorders, 2011, 26, 3
  26. 26
    I. Molchadski, A. D. Korczyn, O. S. Cohen, A. Katzav, Z. Nitzan, J. Chapman, S. Hassin-Baer, The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia, Acta Neurologica Scandinavica, 2011, 123, 2
  27. 27
    Ainhi D. Ha, Joseph Jankovic, Pathophysiology, Pharmacology, and Biochemistry of Dyskinesia, 2011,

    CrossRef

  28. 28
    L.K. Prashanth, Susan Fox, Wassilios G. Meissner, Pathophysiology, Pharmacology, and Biochemistry of Dyskinesia, 2011,

    CrossRef

  29. 29
    Gilberto Fisone, Erwan Bezard, Pathophysiology, Pharmacology, and Biochemistry of Dyskinesia, 2011,

    CrossRef

  30. 30
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef

  31. 31
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef

  32. 32
    Stephen Ku, Graham A. Glass, Age of Parkinson's disease onset as a predictor for the development of dyskinesia, Movement Disorders, 2010, 25, 9
  33. 33
    J.C. Sharma, C.G. Bachmann, G. Linazasoro, Classifying risk factors for dyskinesia in Parkinson’s disease, Parkinsonism & Related Disorders, 2010, 16, 8, 490

    CrossRef

  34. 34
    Santiago Perez-Lloret, Olivier Rascol, Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinsonʼs Disease, CNS Drugs, 2010, 24, 11, 941

    CrossRef

  35. 35
    Thomas Müller, Entacapone, Expert Opinion on Drug Metabolism & Toxicology, 2010, 6, 8, 983

    CrossRef

  36. 36
    Kerstin Buck, Boris Ferger, l-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective, Drug Discovery Today, 2010, 15, 19-20, 867

    CrossRef

  37. 37
    Martin Wolz, Matthias Löhle, Karl Strecker, Uta Schwanebeck, Christine Schneider, Heinz Reichmann, Xina Grählert, Johannes Schwarz, Alexander Storch, Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial, Journal of Neural Transmission, 2010, 117, 11, 1279

    CrossRef

  38. 38
    J. Eric Ahlskog, Seniors with Parkinson's Disease: Initial Medical Treatment, Journal of Clinical Neurology, 2010, 6, 4, 159

    CrossRef

  39. 39
    Kerstin Buck, Boris Ferger, The selective α1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease, Synapse, 2010, 64, 2
  40. 40
    Alessandro Stefani, Mariangela Pierantozzi, Giacomo Koch, Salvatore Galati, Paolo Stanzione, Therapy for dyskinesias in Parkinson’s disease patients, Future Neurology, 2010, 5, 2, 277

    CrossRef

  41. 41
    Susan Fox, Anthony E. Lang, MOVEMENT DISORDERS 4, 2010,

    CrossRef

  42. 42
    Jolyon Meara, Brocklehurst's Textbook of Geriatric Medicine and Gerontology, 2010,

    CrossRef

  43. 43
    Renju Kuriakose, A. Jon Stoessl, Recent Advances in Parkinson’S Disease - Translational and Clinical Research, 2010,

    CrossRef

  44. 44
    M. M. Wickremaratchi, Y. Ben-Shlomo, H. R. Morris, The effect of onset age on the clinical features of Parkinson’s disease, European Journal of Neurology, 2009, 16, 4
  45. 45
    Georg Ebersbach, Alexander Storch, Tolcapone in elderly patients with Parkinson’s disease: A prospective open-label multicenter non-interventional trial, Archives of Gerontology and Geriatrics, 2009, 49, 1, e40

    CrossRef

  46. 46
    Vladimir S. Kostić, Treatment of young-onset Parkinson's disease: role of dopamine receptor agonists, Parkinsonism & Related Disorders, 2009, 15, S71

    CrossRef

  47. 47
    Francesca Sorbo, Alberto Albanese, Levodopa-induced dyskinesias and their management, Journal of Neurology, 2008, 255, S4, 32

    CrossRef

  48. 48
    Alison Fenney, Mandar S. Jog, Christian Duval, Short-term variability in amplitude and motor topography of whole-body involuntary movements in Parkinson's disease dyskinesias and in Huntington's chorea, Clinical Neurology and Neurosurgery, 2008, 110, 2, 160

    CrossRef

  49. 49
    Joohi Shahed, Joseph Jankovic, Movement Disorders, 2008,

    CrossRef

  50. 50
    Jack J Chen, Hubert H Fernandez, Community and Long-Term Care Management of Parkinson???s Disease in the Elderly, Drugs & Aging, 2007, 24, 8, 663

    CrossRef

  51. 51
    Giovanni Fabbrini, Jonathan M. Brotchie, Francisco Grandas, Masahiro Nomoto, Christopher G. Goetz, Levodopa-induced dyskinesias, Movement Disorders, 2007, 22, 10
  52. 52
    Robert A. Hauser, Olivier Rascol, Amos D. Korczyn, A. Jon Stoessl, Ray L. Watts, Werner Poewe, Peter P. De Deyn, Anthony E. Lang, Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa, Movement Disorders, 2007, 22, 16
  53. 53
    Dirk Woitalla, Thomas Mueller, Hermann Russ, Klaus Hock, Doris-Anita Haeger, The Management Approaches to Dyskinesia Vary from Country to Country, Neuroepidemiology, 2007, 29, 3-4, 163

    CrossRef

  54. 54
    Irene A C Halkias, Ihtsham Haq, Zhigao Huang, Hubert H Fernandez, When Should Levodopa Therapy be Initiated in Patients with Parkinson??s Disease?, Drugs & Aging, 2007, 24, 4, 261

    CrossRef

  55. 55
    Thomas Müller, Hermann Russ, Levodopa, motor fluctuations and dyskinesia in Parkinson’s disease, Expert Opinion on Pharmacotherapy, 2006, 7, 13, 1715

    CrossRef

  56. You have free access to this content56
    M. Horstink, E. Tolosa, U. Bonuccelli, G. Deuschl, A. Friedman, P. Kanovsky, J. P. Larsen, A. Lees, W. Oertel, W. Poewe, O. Rascol, C. Sampaio, Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson's disease, European Journal of Neurology, 2006, 13, 11
  57. 57
    Current awareness: Pharmacoepidemiology and drug safety, Pharmacoepidemiology and Drug Safety, 2005, 14, 9
  58. 58
    James H. Bower, Mesfin Teshome, Zenebe Melaku, Guta Zenebe, Frequency of movement disorders in an Ethiopian university practice, Movement Disorders, 2005, 20, 9
  59. 59
    Laser Literature Watch, Photomedicine and Laser Surgery, 2005, 23, 5, 513

    CrossRef

  60. 60
    S. Elizabeth Zauber, Christopher G. Goetz, Dyskinesias in Parkinsonian Syndromes,
  61. 61
    W. H. Oertel, A. Berardelli, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, J. J. Ferreira, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, Early (Uncomplicated) Parkinson's Disease,
  62. 62
    Shen-Yang Lim, Andrew H. Evans, Pain and Paresthesia in Parkinson's Disease,